Hazard Communication
OSHA updates Hazard Communication Standard to align with GHS, affecting labeling and safety data sheets for cosmetics and personal care products.
Aforeworn detected this change in the Cosmetics & Personal-Care (MoCRA) space on July 6, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated High urgency. Indie beauty brands, contract manufacturers, private-label makers, importers/distributors should confirm how it applies to their specific situation before acting. There is a time constraint attached: June 1, 2015 (for manufacturers) and December 1, 2015 (for distributors) – note: this is a historical rule; current compliance is mandatory.. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Cosmetics & Personal-Care (MoCRA) continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.
What changed
OSHA's Hazard Communication Standard now requires labels and safety data sheets to follow GHS criteria, including new hazard classifications, signal words, pictograms, and precautionary statements.
Who it affects
Indie beauty brands, contract manufacturers, private-label makers, importers/distributors
What you must do
Update product labels and safety data sheets to comply with GHS format and classifications.
Deadline
June 1, 2015 (for manufacturers) and December 1, 2015 (for distributors) – note: this is a historical rule; current compliance is mandatory.
Source: https://www.federalregister.gov/documents/2012/03/26/2012-4826/hazard-communication
Never miss a change like this again
Aforeworn watches Cosmetics & Personal-Care (MoCRA) around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.
Start your free trialRelated changes in Cosmetics & Personal-Care (MoCRA)
- FDA Launches One-Day Inspectional Assessments to Strengthen and Expand Oversight
- FDA Grants Seventh Approval under the National Priority Voucher Pilot Program
- FDA Issues Guidance to Improve Collection of Pregnancy Safety Data for Drugs and Biologics
- FDA Expands AI Capabilities and Completes Data Platform Consolidation
- FDA Approves First Treatment for Chronic Hepatitis Delta Virus (HDV) Infection